Case Reports

Drug-induced immune hemolytic anemia associated with albumin-bound paclitaxel


 

Drug-induced immune hemolytic anemia is rare, with only 1 patient in 1 million affected by the condition. Garratty identified 125 drugs indicated in DIIHA of which 11% were antineoplastic agents, and neither paclitaxel nor albumin-bound paclitaxel were included. In addition, we did not find any reports in our own search of the literature. Taxanes are known to cause anemia as a result of their myelosuppressive effects, but an immune hemolysis is rare. To our knowledge, we present here the first case of DIIHA with nab-paclitaxel.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Nodal irradiation improved breast cancer disease-free but not overall survival
Breast Cancer ICYMI
Aromatase inhibitors, bisphosphonates cut postmenopausal breast cancer recurrence
Breast Cancer ICYMI
Why is breast density a weighty matter?
Breast Cancer ICYMI
Do ACOG guidelines protect us from liability?
Breast Cancer ICYMI
ASCO guidelines define use of biomarkers for advanced breast cancer treatment
Breast Cancer ICYMI
Younger breast cancer patients want tailored decision aids
Breast Cancer ICYMI
Weight program effective for breast cancer survivors
Breast Cancer ICYMI
Reduced invasive recurrence after DCIS does not reduce mortality
Breast Cancer ICYMI
Stage 0 Breast Cancer May Not Be the Strongest Indicator of Patient Mortality
Breast Cancer ICYMI
Evidence-based practices can cut breast cancer costs
Breast Cancer ICYMI